Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
mod - the info i just posted plus info on what this company is currently doing should be in the IBOX
Inovio Biomedical to Present at Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Oct. 21, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced today that the company will present corporate updates at two investor conferences next week. Dr. J. Joseph Kim, president and CEO, was also invited to participate on a panel, “Predicting a Frontrunner in the Race Against Pandemic Flu,” at BIO Investor Forum.
4th Annual BIOCOM Investor Conference
Hyatt Regency La Jolla
San Diego, California
12:00 p.m., Tuesday, October 27th
Investor Presentation: Avtar Dhillon, MD, Executive Chairman
8th Annual BIO Investor Forum
The Palace Hotel
San Francisco, California
8:00 a.m., Thursday, October 29th
Predicting a Frontrunner in the Race Against Pandemic Flu
Panelist: J. Joseph Kim, PhD, President and CEO
10:00 a.m., Thursday, October 29th
Investor Presentation: J. Joseph Kim, PhD, President and CEO
Webcast, live and archived
About Inovio Biomedical Corporation
Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH’s Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to, among other things, our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the quarterly period ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Source: Inovio Biomedical Corporation
Investors:
Inovio Biomedical
Bernie Hertel, 858-410-3101
or
Media:
Richardson & Associates
Jeff Richardson, 805-491-8313
Inovio Biomedical Board of Directors Adds Two New Members
David J. Williams, Former Chairman & CEO of the Vaccines Business of Sanofi-Aventis Group, and Keith H. Wells, a Vaccine Developer for The Salk Institute, Will Help Guide Inovio’s Development of Advanced Vaccines
SAN DIEGO--(BUSINESS WIRE)--Oct. 26, 2009-- Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine design, development and delivery, announced that its board of directors elected David J. Williams, former chairman and CEO of Sanofi Pasteur, the vaccine business of Sanofi-Aventis Group, and Keith H. Wells, a senior member of the Biologics Consulting Group and former director of vaccine development for The Salk Institute, to the board.
David J. Williams retired in 2008 as chairman & CEO of Sanofi Pasteur, the vaccines business of the Sanofi-Aventis Group. His leadership moved the company from a niche vaccine business to the global leader in vaccine development, production and sales, with revenues of more than $6 billion in 2007. Under his guidance, more than a billion doses of lifesaving vaccines were administered to more than 500 million people around the world each year, representing more than 25% of the global vaccine market. During his tenure the company licensed more than 30 new vaccines and launched hundreds of business development deals.
For the past 20 years, Keith H. Wells, a senior member of Biologics Consulting Group, has overseen all facets of vaccine development including process development and validation, manufacturing operations, and U.S. and European regulatory strategy for several international companies. He has directed vaccine development at Acambis, PLC, Oravax, and The Salk Institute, and provided R&D support to vaccine manufacturing at Merck & Co. He has a Ph.D. in microbiology and immunology from State University of New York Health Science Center at Syracuse.
Dr. J. Joseph Kim, president & CEO of Inovio, said: “These two business leaders each have multiple decades of experience leading and executing the development and commercialization of cutting-edge vaccine technology and important new vaccines. Their expertise will be invaluable to Inovio as we advance a new generation of vaccines - DNA vaccines delivered using the potency-enhancing capabilities of electroporation - that are displaying superior results and potential to not only prevent but treat challenging infectious diseases and cancers.”
Inovio Biomedical’s other board members are Avtar Dhillon, M.D., Inovio’s executive chairman; Dr. J. Joseph Kim, Inovio’s president & CEO; Simon Benito, former senior vice president of Merck’s vaccine division; Morton Collins, general partner of Battelle Ventures; and Ng Tee Khiang, co-founder of Evia Capital Partners and Evia Growth Opportunities.
About Inovio Biomedical Corporation
Inovio Biomedical is focused on the design, development, and delivery of a new generation of vaccines, called DNA vaccines, to prevent and treat cancers and infectious diseases. The company’s SynCon™ technology enables the design of DNA-based vaccines capable of protecting against both known and new, unknown strains of pathogens such as influenza. Inovio’s proprietary electroporation-based DNA vaccine delivery technology has been shown by initial human data to safely and significantly increase gene expression and immune responses. Inovio’s clinical programs include HPV/cervical cancer (therapeutic) and HIV vaccines. An IND has been filed for an avian influenza vaccine. Inovio is developing its universal and avian influenza vaccines in collaboration with scientists from the University of Pennsylvania, the National Microbiology Laboratory of the Public Health Agency of Canada, and the NIH’s Vaccine Research Center. Other partners and collaborators include Merck, Tripep, University of Southampton, National Cancer Institute, and HIV Vaccines Trial Network. More information is available at www.inovio.com.
This press release contains certain forward-looking statements relating to, among other things, our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2008, our Form 10-Q for the quarterly period ended June 30, 2009, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Source: Inovio Biomedical Corporation
Investors:
Inovio Biomedical
Bernie Hertel, 858-410-3101
or
Media:
Richardson & Associates
Jeff Richardson, 805-491-8313
what about a total blitz for the first hr
put in all buy orders NITE's opener
im in for a couple of grand $$ wise if anyone is willing to double me up
check LLEG they were on there a few days ago
well i hope everyone is right i just got 30k for 0.1310
playing the lottery just filled it
any one have google wave?
whats their twitter name?
yup im still here :-P
can anyone get any fills???
gone from Hold to Buy
lvl 2 anyone?
whats the current o/s
if 3 years is long , then no im not selling actually im now building more on the dips
i dont know about that but i wonder if Laidlaw is listed with http://www.biomassmagazine.com/ in there industrial directory that closed october 5th
hopefully one in a few more days and then a few more good prs in the next 3 weeks would boost this
with XCEL , LLEG has the upper hand now against the others in berlin and also in NY , it simply speaks for itself the latest PR is just the tip of the iceberg
just dipped time to cash in i just did :)
that cl0sed at 11/12pm , but no matter ppl in the uk can still trade
good time to buy more IMO
Next hourly spike should happen in about 25 mins
by the time this is done we will all be our own bosses
Merrill Lynch/BOA just posted this
+102.70% Up0.00 0.01 222,471,851
% Change Change Last Volume: Above Avg
2 mms already waiting for 0.02
with movement like this people that sell are INSANE!!!
fine im putting all in at $2 5 Million
Laidlaw is in the process of finalizing its application to the New Hampshire Site Evaluation Committee for its project, according to the company. The committee’s approval is required in order to move forward. Rail access at the facility could open the door to utilizing cheap fuel from other regions such as storm debris from the southern U.S
well it was trading at 50-70 cents 5 years ago
who cares i just bought them back for 16 :-P
why not just put sell orders for 100k for .0025 limit and a few buy 100k orders at 23
i just got in with 1Mil at 18/19 today
is this good or bad for lleg ???
http://www.cnn.com/2009/TECH/science/03/30/biochar.warming.energy/index.html
By Azadeh Ansari
CNN
Decrease font Decrease font
Enlarge font Enlarge font
ATHENS, Georgia (CNN) -- Over the railroad tracks, near Agriculture Drive on the University of Georgia campus, sits a unique machine that may hold the solution to big environmental problems such as energy, food production and even global climate change.
Biochar's high carbon content and porous nature can help soil retain water, nutrients, protect soil microbes.
Biochar's high carbon content and porous nature can help soil retain water, nutrients, protect soil microbes.
"This machine right here is our baby," said UGA research engineer Brian Bidens, who is one of a handful of researchers working on alternative ways to recycle carbon.
Biden feeds a octagonal shaped metal barrel with "biomass" - a substance made of any forest, agricultural or animal waste with a high carbon content. Often biomass products are woodchips, corn husks, peanut shells even chicken manure.
Under intense heat, sometimes above 1,000 degrees Fahrenheit, the organic matter is cooked through a thermochemical process called "pyrolysis".
In a few hours, organic trash is transformed into renewable treasures such as fuel for vehicles and charcoal-like pellets called biochar that can enrich soil for farming.
Don't Miss
* In Depth: Edge of Discovery
* Obama invites major economies to energy forum
Biochar is considered by many scientists to be the "black gold" for agriculture.
Its high carbon content and porous nature can help soil retain water, nutrients, protect soil microbes and ultimately increase crop yields while acting as natural carbon sink - locking or sequester carbon in the ground.
Biochar helps clean the air two ways: by preventing rotting biomass from releasing harmful CO2 into the atmosphere, and by allowing plants to safely store CO2 they pull out of the air during photosynthysis. See more about how biochar works »
"Soil acts as an enormous carbon pool, increasing this carbon pool could significantly contribute to the reduction of CO2 in the atmosphere," said Steiner. "It gives us a chance to produce carbon negative energy."
Worldwide use of biochar could cut CO2 levels by 8 parts per million within 50 years, according to NASA scientist James Hansen.
Global carbon levels in the air have been steadily increasing at an alarming rate since the 1980s, according to NOAA. Since 2000, increases of 2 parts per million of CO2 have been common, according to NOAA. During the 1980s rates increased by 1.5 ppm per year.
The process of making biochar can also lead to other valuable products.
Some of the gases given off during the process can be converted to electricity, others can be condensed and converted to gasoline, and there are also some pharmaceutical applications for the by-products, said Danny Day President and CEO of Epidra, a private firm in Athens, Georgia currently exploring industry applications and process of making biochar.
Although scientists look to biochar to improve the future, its origin lies in the past.
For centuries indigenous South Americans living in the Amazon Basin used a combination of charred animal waste and wood to make "terra preta" - which means black earth, in Portuguese.
Thousands of years after its creation, the terra preta soil remains fertile without need for any added fertilizer, experts say.
"These terra preta soils are older than 500 years and they are still black soil and very rich in carbon," said Steiner.
By using biochar concepts, terra preta soils have been proven to remain fertile for thousands of years, preventing further harmful deforestation for agricultural purposes. But still more large-scale tests need to be conducted before biochar technology can be rolled out on a global scale.
Day says biomass -- that otherwise would be thrown away --could be developed into entirely new markets for biofuels, electricity, biomass extracts and pharmaceutical applications, in addition to biochar.
advertisement
"We have 3 billion people out there who are at risk for climate change and they can be making money solving our global problem," said Day.
Industries can now begin to look at farmers around the world and pay them for their agricultural wastes, said Day. "They can become the new affluent."
E-mail to a friend E-mail to a friend
Share this on:
Mixx Digg Facebook del.icio.us reddit StumbleUpon MySpace
| Mixx it | Share
that was my 1st buy in im a newcomer i like anything green stock
i hope so cause im in at 500k at 15
ans whats the answer?
anyone up to purchasing a few 0.0011s just before bell to keep the price unch?
why dont every one put in a late bid for 0.0008 just before the bell
better than $0 or to pay more though right?
12 inches and 20 mph winds